Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion

In Vivo

Volumn 14, Issue 5, 2000, Pages 565-570

  Al Atrash, Gheath ^a   Kitson, Richard P ^a   Xue, Yaming ^a   Goldfarb, Ronald H ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Aprotinin; BB 94; Matrix metalloproteinases; Urokinase plasminogen activator (uPA)

Indexed keywords

APROTININ; BATIMASTAT; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PLASMIN INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ARTICLE; BIOASSAY; CELL INVASION; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DEGRADATION; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ANALYSIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LYMPHOCYTE; METABOLIC INHIBITION; MOLECULAR WEIGHT; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

EID: 0034579833     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
2. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic
3. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2
4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo
5. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
6. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
7. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells
8. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer
9. Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleen
10. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells
11. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases
12. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells
13. Plasminogen activators, tissue degradation, and cancer
14. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation
15. Urokinase induces receptor mediated brain tumor cell migration and invasion
16. Proteolytic enzymes in cancer invasion and metastasis
17. Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study
18. Plasminogen activation and regulation of pericellular proteolysis
19. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis
20. Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases
21. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression
22. Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells
23. Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways
24. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells
25. The cleavage of pro-urokinase type plasminogen activator by stromelysin- 1
26. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3)
27. Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor
28. Identification and localization of urokinase-type plasminogen activator in human NK-cells
29. Production of plasminogen activator by human natural killer cells. Large granular lymphocytes
30. Matrix metalloproteinases produced by rat IL-2 activated natural killer cells
31. Matrix metalloproteinases of human NK cells
32. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression
33. Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein
34. Zymographic analysis of extracellular, released and cell- associated proteases of rat interleukin 2-activated natural killer (A-NK) cells
35. Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: Kinetics and inhibitor profiles
36. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes
37. The susceptibility of urokinase to affinity labeling by peptides of arginine chloromethyl ketone
38. Inactivation of the plasminogen activator from HeLa cells by peptides of arginine chloromethyl ketone